View all newsletters
Receive our newsletter - data, insights and analysis delivered to you
April 9, 2017

Hikma signs settlement agreement over Jazz’s Xyrem patent litigation

Hikma Pharmaceuticals has entered a settlement agreement that resolves patent litigation related to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution at 500mg/ml per product.

Hikma Pharmaceuticals has entered a settlement agreement that resolves patent litigation related to Jazz Pharmaceuticals’ Xyrem (sodium oxybate) oral solution at 500mg/ml per product.

Free Report
img

Spot leading innovative companies with GlobalData’s Innovation Scorecard

Innovation remains a necessity in a disruptive ecosystem, as continuous innovation allows companies to adapt, evolve, and grow through disruption. Using our in-house alternative datasets, we are excited to launch GlobalData’s Innovation Scorecard. This scorecard will allow clients to rank 3,500+ companies on their innovation activity, impact, and disruptive potential across geography, sector, and theme. The scorecard provides a data-driven framework to rank leading companies on the potential of their intellectual property (IP) portfolio. GlobalData’s Innovation Scorecard focuses not only on the activity of innovation in the organization but also on its impact and disruptive potential using the 3I framework: Intensity, Impact, and Ingenuity. The tool helps clients to identify the most innovative companies that are disruptive leaders and challengers and can create alpha for their portfolio using the insights driven by 19+ high-value KPIs. Download our report to find out more about this innovative tool. Key findings derived from this tool include:
  • Alphabet, Tencent, and Qualcomm are the top three innovative companies in the last 10 years
  • The scorecard finds Technology & Communications and Pharma & Healthcare as the two main sectors driving innovation
  • Loreal placed as ‘Disruptive Leader’ in the Consumer sector, while Revlon has been identified as a traditional laggard
  • Companies such as Etsy and H&M are challenging retail ‘Disruptive Leaders’ Amazon and Walmart
by GlobalData
Enter your details here to receive your free Report.

Under the agreement, Hikma and its wholly owned subsidiary West-Ward Pharmaceuticals will acquire the rights from Jazz to sell an authorised generic (AG) of Xyrem in the US market, beginning 1 January 2023 or earlier. 

West-Ward Pharmaceuticals CEO Mike Raya said: "We are very pleased to have reached an agreement with Jazz with terms that are favourable for both parties. 

“Sodium oxybate is an exciting product in our pipeline and supports our strategy of developing a differentiated product portfolio to drive sustainable growth for our US business."

A form of gamma hydroxybutyrate (GHB), Sodium oxybate is a central nervous system (CNS) depressant and causes changes in alertness and trouble breathing. 

"We are very pleased to have reached an agreement with Jazz with terms that are favourable for both parties."

The product will be marketed through the Xyrem Risk Evaluation and Mitigation Strategy (REMS) programme. 

The six months AG agreement has an option to be extended for up to a total of five years. 

Hikma also obtained a licence to market generic sodium oxybate, pursuant to its ANDA at the end of the AG term.

The company will pay a royalty to Jazz on net sales of the AG product, as well as for its supply.

It will reimburse Jazz for a portion of the service costs associated with the operation of the Xyrem REMS and distribution of the AG. 

Through its wholly owned US subsidiary Roxane Laboratories, Hikma submitted the first ANDA with Paragraph IV certification for sodium oxybate oral solution.

Related Companies

Free Report
img

Spot leading innovative companies with GlobalData’s Innovation Scorecard

Innovation remains a necessity in a disruptive ecosystem, as continuous innovation allows companies to adapt, evolve, and grow through disruption. Using our in-house alternative datasets, we are excited to launch GlobalData’s Innovation Scorecard. This scorecard will allow clients to rank 3,500+ companies on their innovation activity, impact, and disruptive potential across geography, sector, and theme. The scorecard provides a data-driven framework to rank leading companies on the potential of their intellectual property (IP) portfolio. GlobalData’s Innovation Scorecard focuses not only on the activity of innovation in the organization but also on its impact and disruptive potential using the 3I framework: Intensity, Impact, and Ingenuity. The tool helps clients to identify the most innovative companies that are disruptive leaders and challengers and can create alpha for their portfolio using the insights driven by 19+ high-value KPIs. Download our report to find out more about this innovative tool. Key findings derived from this tool include:
  • Alphabet, Tencent, and Qualcomm are the top three innovative companies in the last 10 years
  • The scorecard finds Technology & Communications and Pharma & Healthcare as the two main sectors driving innovation
  • Loreal placed as ‘Disruptive Leader’ in the Consumer sector, while Revlon has been identified as a traditional laggard
  • Companies such as Etsy and H&M are challenging retail ‘Disruptive Leaders’ Amazon and Walmart
by GlobalData
Enter your details here to receive your free Report.

NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU

Thank you for subscribing to Pharmaceutical Technology